A groundbreaking discovery in the field of breast cancer treatment has emerged, offering hope to patients with PIK3CA-mutated breast cancer. The addition of a drug called zovegalisib to the existing treatment regimen has shown remarkable results, especially for those with hormone receptor (HR)-positive/HER2-negative advanced breast cancer.
The ReDiscover trial, presented at the 2025 San Antonio Breast Cancer Symposium, revealed that combining zovegalisib with fulvestrant led to significant improvements in certain patient populations. Among 31 patients with measurable disease and no PTEN or AKT co-mutations, the objective response rate (ORR) was an impressive 38.7%, and the median duration of response was a promising 12.9 months.
But here's where it gets controversial: the ORR varied depending on the presence of ESR1 mutations. Patients with ESR1-mutated disease experienced an ORR of 60.0%, while those without had a lower response rate of 28.6%. This suggests that the combination therapy may be particularly effective for this specific subgroup.
Furthermore, the safety profile of zovegalisib was reassuring, with mostly low-grade, reversible adverse effects related to targeting PI3K. No severe grade 4 or treatment-related AEs were observed, despite a high relative dose intensity.
Lead study author, Dr. Cristina Saura, emphasized the potential of zovegalisib, stating, "These findings highlight the crucial role of mutated PI3Kα in HR-positive/HER2-negative breast cancer and the need for targeted therapies."
The study enrolled 64 adults with PIK3CA-mutated disease who had previously undergone CDK4/6 inhibition and endocrine therapy. These patients received the recommended phase 2 dose of zovegalisib, and the results were encouraging.
However, it's important to note that the study had a relatively small sample size, and further research is needed to validate these findings.
So, what do you think? Is this a game-changer for breast cancer treatment? Join the discussion and share your thoughts on this exciting development in cancer research!
